Infectious Disease Fellowship Program
Christa S. Zerbe, M.D., MS (She/Her/Hers)
Director, Infectious Disease Fellowship Program
Medical Director, Clinical Patient Services Unit LCIM
Senior Staff Clinician
Specialty(s): Infectious Disease Provides direct clinical care to patients at NIH Clinical Center
Major Areas of Research
- Chronic Granulomatous Disease and the Inflammatory and Infectious complications
- Carriers of X-linked CGD
- Anti-Cytokine Autoantibody Diseases
- Disseminated Non-Tuberculosis Mycobacterial Infections
As a Senior Staff Clinician, Dr. Zerbe focuses on the clinical care of patients with CGD and acquired anti-cytokine antibody syndromes. Her research includes studies in patients with anti-cytokine antibodies both nationally and internationally in Thailand continuing the research and treatment of patients who suffer from these syndromes in order to further our understanding of non-HIV acquired immunodeficiency. Additionally, Dr. Zerbe oversees the care and research regarding patients with and affected carriers of the gene resulting in Chronic Granulomatous Disease. Her collaboration with the NIDDK and with outside collaborators resulted in a UO1 grant as well as several protocols looking at therapies aimed at the inflammatory complications in this disease.
An alumnus of The University of Pittsburgh School of Medicine, Dr. Zerbe completed her Internal Medicine residence at the University of Maryland Hospital before transitioning into the ABIM Research Pathway for Infectious Disease Fellowship at the NIH. Dr. Zerbe serves as Principal Investigator on numerous protocols within NIAID. She is the director of the Infectious Disease training program at the NIH and recently began overseeing the joint NIH-Johns Hopkins Hospital Transplant Oncology ID training program.
Mycobacterial and Opportunistic Infections in HIV-Negative Thai and Taiwanese Patients Associated With Autoantibodies to Interferon-gamma NCT00814827
Elemental Diet for Treatment of Inflammatory Bowel Disease in Patients With Chronic Granulomatous Disease NCT03983837
Safety and Efficacy of Tofacitinib for Chronic Granulomatous Disease With Inflammatory Complications NCT05104723
Microbial, Immune, and Metabolic Perturbations by Antibiotics (MIME Study) NCT02707042
Falcone EL, Han Y, Kreuzburg S, Heller T, Church JA, Grou C, Calderon V, Subramanian P, Deming C, Conlan S, Segre JA, Holland SM, Zerbe CS. Exclusive enteral nutrition induced sustained changes in the microbiota and improved inflammatory bowel disease in a pediatric patient with chronic granulomatous disease. J Allergy Clin Immunol Pract. 2021 Feb;9(2):1011-1014.e2.
Bhattacharya S, Marciano BE, Malech HL, Quezado M, Holland SM, De Ravin SS, Zerbe CS, Heller T. Safety and Efficacy of Ustekinumab in the Inflammatory Bowel Disease of Chronic Granulomatous Disease. Clin Gastroenterol Hepatol. 2022 Feb;20(2):461-464.e2.
Marciano BE*, Zerbe CS*, Falcone EL, Ding L, DeRavin SS, Daub J, Kreuzburg S, Yockey L, Hunsberger S, Foruraghi L, Barnhart LA, Matharu K, Anderson V, Darnell DN, Frein C, Fink DL, Lau KP, Long Priel DA, Gallin JI, Malech HL, Uzel G, Freeman AF, Kuhns DB, Rosenzweig SD, HollandSM. X-linked carriers of chronic granulomatous disease: Illness, lyonization, and stability. J Allergy Clin Immunol. 2018 Jan;141(1):365-371
Rocco JM, Rosen LB, Hong GH, Treat J, Kreuzburg S, Holland SM, Zerbe CS. Bortezomib treatment for refractory nontuberculous mycobacterial infection in the setting of interferon gamma autoantibodies. J Transl Autoimmun. 2021 May 4;4:100102.
Hong GH, Ortega-Villa AM, Hunsberger S, Chetchotisakd P, Anunnatsiri S, Mootsikapun P, Rosen LB, Zerbe CS, Holland SM. Natural History and Evolution of Anti-Interferon-γ Autoantibody-Associated Immunodeficiency Syndrome in Thailand and the US. Clin Infect Dis. 2019 Aug 20.
Moutsopoulos NM, Zerbe CS, Wild T, Dutzan N, Brenchley L, DiPasquale G, Uzel G, Axelrod KC, Lisco A, Notarangelo LD, Hajishengallis G, Notarangelo LD, Holland SM.,Interleukin-12 and Interleukin-23 Blockade in Leukocyte Adhesion Deficiency Type 1 N Engl J Med. 2017 Mar 23;376(12):1141-1146.